For Immediate Release December 1, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),  a pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs, today announced that it has received the third tranche of funding  under the recently announced committed minimum financing of $2,000,000 with RB Capital  Partners Inc. This brings the total to $800,000 that the Company has received under this financing.  The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment  on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer  compound targeted for pancreatic cancer. 

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, “We continue to be amazed  by both the ingenuity and the work ethic of Sunshine Biopharma’s leadership team. This is money  well spent as every dollar is dedicated to the understanding and advancement of life-saving  medicines. RB Capital is proud to invest in a company that is relentlessly working towards  developing a Coronavirus treatment. The implications of such a treatment are boundless.”  

Sunshine Biopharma Inc. CFO, Camille Sebaaly shared, “We have a lot of important work under  way, and the continued funding by RB Capital Partners enables us to keep our focus on the  advancement of our oncology and antiviral drugs. We look forward to continue working with them  as it is clear that they truly believe in our Company’s vision.”  

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of  Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM 

PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials  on COVID-19 patients.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release November 24, 2020

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs today announced that it is pushing ahead with its Anti-Coronavirus  drug development program. While the recent announcements about effective vaccines on the 

horizon is a cause for celebration, Sunshine Biopharma believes that a treatment for  Coronavirus infections continues to be essential for any robust healthcare system. This is  particularly important in view of the fact that gaps and lapses will likely occur during vaccine  implementation and people may fall ill and require treatment. In addition, a treatment that can be  taken orally at home, much like an antibiotic, would be an ideal complement for vaccination. 

“SARS-CoV-2, the causative agent of COVID-19, is the third in a line of Betacoronaviruses that  have caused serious human health threats in the past. The first two were SARS-CoV that  appeared in 2002 and MERS-CoV in 2015,” said Dr. Steve N. Slilaty, CEO of Sunshine  Biopharma. “There is nothing that says that another Betacoronavirus with a potential for causing  yet another serious threat to human health won’t appear in the future. It is critical for us to have  a treatment for today and as part of our preparedness for the future,” he added. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of  COVID-19, the current ongoing pandemic that has claimed the lives of over 1.3 million people  worldwide since it first appeared in December 2019. There are currently no drugs that can  effectively arrest replication of the virus in people who have contracted the illness. On May 22,  2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which  were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to  multiply and cause illness. Sunshine Biopharma has since screened the library and identified a  lead Anti-Coronavirus compound (SBFM-PL4). The Company is currently conducting a series of  in vitro tests to evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2  papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral  replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell  culture testing stage and assessment in Coronavirus infected mice before entering human  clinical trials.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information: 

Sunshine Biopharma, Inc. 

Camille Sebaaly, CFO 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs today announced that it has entered into a collaboration agreement with Montreal-Based company for the purposes of advancing the development of Sunshine  Biopharma’s anticancer compound, Adva-27a. The goal of this collaboration is to develop and  implement chemical synthesis procedures for Adva-27a and test the resulting material in various  types of cancer cells grown in culture. Based on the cell culture results, Sunshine’s drug  development partner will conduct mice studies in preparation for entry of Adva-27a into clinical  trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and  will be performed at McGill University’s Jewish General Hospital in Montreal, Canada. 

“We are delighted to be working with our new Montreal-Based partner and their fully integrated  team of experts in chemical synthesis, cell culture assays and mice studies,” said Camille  Sebaaly, CFO of Sunshine Biopharma. 

About Sunshine Biopharma and Adva-27a 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not 

be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information: 

Sunshine Biopharma, Inc. 

Camille Sebaaly, CFO 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release November 10, 2020

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Pink: “SBFM”) today announced that it has signed an agreement with JOAH International Pte., Ltd., headquartered in Singapore for distribution of Essential-9TM in Asia and the Far East. Sunshine Biopharma’s Essential-9TM is a nutritional supplement tablet comprised of a balanced formula of the 9 essential amino acids that the human body cannot make. Essential-9TM is authorized for marketing by Health Canada under NPN 80089663.

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, chronic fatigue, weight gain, and weakened immune system. Sunshine Biopharma’s Essential-9^TM provides a balanced formula of all 9 Essential Amino Acids in free-form, ready to be absorbed. Essential-9TM is suitable for everyone: Vegans, Seniors, Dieters, Athletes, and everyone looking to increase their health. In North America, Essential-9TM is available on Amazon.com and Amazon.ca.

“Offering accessibility to Essential-9TM in this important economic region is a major milestone in our marketing program,” said Camille Sebaaly, Chief Financial Officer of Sunshine Biopharma.

About Sunshine Biopharma

Sunshine Biopharma is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, Sunshine Biopharma is engaged in the development and commercialization of science-based nutritional supplements. In addition, to working with the University of Georgia on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to the COVID-19 treatment and Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:

Camille Sebaaly, CFO Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

Science Based Nutrition

For Immediate Release October 26, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the second tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $550,000 that the Company has received under this financing. The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.1 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM- PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.

“We are excited about the financing arrangement we have in place with RB Capital as it provides with the funding required for our research projects,” said Camille Sebaaly, Chief Financial Officer of Sunshine Biopharma.

About Sunshine Biopharma

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:

Camille Sebaaly, CFO Sunshine Biopharma Inc.

Direct Line: 514-814-0464 camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com

Phoenix, October 22nd, 2020 (Newsfile Corp.) — The Stock Day Podcast welcomed Sunshine Biopharma (SBFM) (“the Company”), a company working on the development of a treatment for COVID-19, as well as the development of Adva-27a, a unique anticancer compound. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host Everett Jolly.

Jolly began the interview by asking Dr. Slilaty about the Company’s background and current projects. “Sunshine Biopharma is an R&D company and we’re focused on two areas of research. One is oncology and the second is antiviral compounds,” explained Dr. Slilaty. “In the area of oncology, we have an anticancer drug that works on multidrug resistant cancers, such as pancreatic cancer and small cell lung cancer,” he continued. “In the area of antivirals, we are working on a protease inhibitor for coronavirus.”

Jolly then asked about the difference between the Company’s compound, SBFM-PL4, and Regeneron’s. “The President [President Trump] received the monoclonal antibody cocktail that was developed by Regeneron,” explained Dr. Slilaty. “It’s very effective in that it’s able to neutralize the coronavirus in the system, however it has to be administered by injection in the hospital,” said Dr. Slilaty. “We’re working on something totally different. It’s a protease inhibitor, which will be in the form of a pill that people can take at home.”

Jolly then commented on a recent press release regarding the Company’s partnership with the University of Georgia. “How did that come about and what makes you excited about that whole process?”, asked Jolly. Dr. Slilaty elaborated on his relationship with University of Georgia’s Dr. Scott Pegan, and shared that the Company is now working with the University on the development of SBFM-PL4, for use as a treatment for coronavirus. “The University of Georgia has expertise in the area of protease inhibitors, as well as in doing the assays and mouse studies involving coronavirus.”

“How does the coronavirus attack the body?”, asked Jolly. “The alpha coronavirus causes the common cold and the beta coronavirus is referred to as SARS,” explained Dr. Slilaty, adding that out of four types of coronavirus the alpha and beta versions are the most dangerous. “These are the ones we’re working on developing inhibitors for to completely arrest the ability of these viruses to replicate in the human body,” said Dr. Slilaty. “When the virus enters the body, it immediately begins to replicate,” he explained. “Some of the proteins generated are able to shut down the immune response of the human body.”

“Where are you at in the process of bringing your SBFM-PL4 to the marketplace?”, asked Jolly. Dr. Slilaty shared that there are several companies working on vaccines and antibodies to fight the coronavirus, however the Company’s protease inhibitor is an early stage solution. “We’re very excited about it and we’re optimistic that we will be able to begin the mice studies before the end of the year,” said Dr. Slilaty.

To close the interview, Dr. Slilaty shared that the Company will remain dedicated to developing a solution for the coronavirus in an effort to have a positive impact on the world during this pandemic.

To hear Dr. Steve Slilaty’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7711456-ceo-of-sunshine-biopharma-dr-steve-slilaty-is-featured-on-the-stock-day-podcast

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About Sunshine Biopharma

In addition to working on the development of SBFM-PL4 as a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information:

Sunshine Biopharma, Inc.

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media

(602) 821-1102

For Immediate Release October 19, 2020

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into an Agreement with the University of Georgia for the purposes of working together to advance the development of Sunshine Biopharma’s recently announced Anti-Coronavirus lead compound, SBFM-PL4. The goal of this cutting-edge collaboration is to develop SBFM-PL4, a protease inhibitor, as a treatment for Coronavirus infections. This new treatment is based on the technology described in Sunshine Biopharma’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections. Sunshine’s SBFM-PL4, will be put through a series of in vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture testing stage and assessment in Coronavirus infected mice before entering human clinical trials.

“We are delighted to be working with the University of Georgia and Dr. Scott Pegan and his team of Coronavirus experts who share our vision of developing a treatment that would make a difference in the fight against the pandemic,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma’s Coronavirus Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the current ongoing pandemic that has claimed the lives of over 1,000,000 people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness.

About the University of Georgia

As part of its land grant tripartite mission, the University of Georgia is committed to creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery as well as the Colleges of Pharmacy are excited to be a part of this ground-breaking research related to discovery of new treatment options for COVID-19. Profs. Scott Pegan, and David Crich will be working with Sunshine Biopharma to spearhead the study of novel therapeutics for the

prevention and spread of COVID-19. This interdisciplinary effort involves state of the art approaches in chemical synthesis and drug screening. This continues University of Georgia’s long-standing tradition in translating scientific breakthroughs to address real world health concerns.

About Sunshine Biopharma

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information:

Sunshine Biopharma, Inc. Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

For Immediate Release – October 7, 2020.

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs today announced that it has screened and subsequently identified
a lead compound from its library of Coronavirus protease inhibitors. The screening which
pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy
under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and
Interim Associate Head of Pharmaceutical and Biomedical Sciences. The Company is currently
looking into expanding its collaboration with the University of Georgia and will be seeking the
University’s assistance in advancing the development of the newly identified lead compound.
The compounds which were screened are based on the technology described in Sunshine
Biopharma’s recently filed patent application covering small molecules which can be used to
treat Coronavirus infections. Next, Sunshine’s lead compound will be put through a battery of in
vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like
protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition
to cleaving the virus encoded polyprotein at three different sites to generate mature virus
proteins, PLpro also cleaves certain host proteins resulting in suppression of the host immune
response and allowing virus replication to proceed unchecked which enhances the virus’ ability
to cause severe morbidity. Following the in vitro tests, the lead compound will be moved forward
to the cell culture testing stage followed by mice studies before entering human clinical trials.

About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives of over 1,000,000 people
worldwide since it first appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have contracted the illness. On May 22,
2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to
multiply and cause illness.

About the University of Georgia
As part of its land grant tripartite mission, the University of Georgia is committed to
creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery as
well as the Colleges of Pharmacy are excited to be a part of this ground-breaking research
related to discovery of new treatment options for COVID-19. Profs. Scott Pegan, and David
Crich will be working with Sunshine Biopharma to spearhead the study of novel therapeutics for
the prevention and spread of COVID-19. This interdisciplinary effort involves state of the art
approaches in chemical synthesis and drug screening. This continues University of Georgia’s
long-standing tradition in translating scientific breakthroughs to address real world health
concerns.

About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to
date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant
Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer
cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to
be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ
materially from those anticipated or expected, including statements related to the amount and timing of expected
revenues statements related to our financial performance, expected income, distributions, and future growth for
upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by
the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain
events could differ materially from those projected in or contemplated by the forward-looking statements due to a
number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock
market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC
filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as
new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the
near and long term. Additional service offerings may expose us to additional legal and regulatory costs and
unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of
which cannot be predicted at this time.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

For Immediate Release, August 25, 2020.

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs today announced that it has completed the synthesis of four
different potential inhibitors of Coronavirus protease. These compounds are based on the
technology described in the Company’s recently filed patent application covering small
molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the
causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these
molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded
proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at
three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins
resulting in suppression of the innate immune response thereby allowing the virus to multiply
unhindered. Based on the binding affinity results, Sunshine will select a lead compound for
further Anti-Coronavirus drug development.

About Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and
commercialization of oncology and antiviral drugs. In addition, to working on the development of
a treatment for COVID-19, Sunshine biopharma is engaged in the development Adva-27a, a
unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of
Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells,
Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for
Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General
Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual
property pertaining to Adva-27a and the Coronavirus protease inhibitors under development.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the success of the Company’s development,
events conditioned on stockholder or other approval, or otherwise as to future events, such statements
are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to
certain risks and uncertainties that could cause actual results to differ materially from the statements
made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com